Bilateral De Quervain Syndrome after Aromatase Inhibitor Administration: A Case Report and Review of the Literature by Papadimitriou, Konstantinos et al.
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2012, Article ID 810428, 5 pages
doi:10.1155/2012/810428
Case Report
Bilateral De Quervain Syndromeafter Aromatase Inhibitor
Administration:A Case Reportand Reviewof the Literature
Konstantinos Papadimitriou,1 Panteleimon Kountourakis,1,2 EmmanouilMorakis,3
Vassilios Vassiliou,4 VasileiosBarbounis,5 andAlexandrosArdavanis2
1Department of Medical Oncology, BOC Oncology Centre, Nicosia, 2006 Strovolos, Cyprus
2First Department of Medical Oncology, Saint Savvas Anticancer Hospital, Athens, Greece
3First Orthopedic Surgery Department, Evangelismos Hospital, Athens, Greece
4Department of Radiation Oncology, BOC Oncology Centre, Nicosia, 2006 Strovolos, Cyprus
5Medical Oncology Unit, Hipokrateion Hospital, Athens, Greece
Correspondence should be addressed to Panteleimon Kountourakis, pantkount@gmail.com
Received 18 November 2011; Accepted 1 February 2012
Academic Editor: Faustino R. P´ erez-L´ opez
Copyright © 2012 Konstantinos Papadimitriou et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Aromatase inhibitors are widely used as one of the main treatment options of both early and advanced hormone receptor-positive
breast cancer in postmenopausal women. Unfortunately, musculoskeletal symptoms are often presented in patients treated with
aromatase inhibitors (AIs), and, although the pathogenesis is unknown, postulated mechanisms have been described. Herein, to
our knowledge, we present the ﬁrst report of bilateral De Quervain syndrome related with AIs therapy with a review of the relevant
literature.
1.Introduction
Recently, aromatase inhibitors (AIs) have substituted tamox-
ifen as the preferred adjuvant treatment of both early
and advanced hormone-responsive breast cancer in post-
menopausal women. AIs have been proven to be more eﬀec-
tive than tamoxifen, showing improved outcome and lower
incidence of distant recurrences. In addition, they have a
more favorable toxicity proﬁle compared to tamoxifen, with
lower rates of thromboembolic events and endometrium
cancer occurrence. However, their main side eﬀects include
bone mineral density reduction and musculoskeletal pain
symptoms. These musculoskeletal symptoms present either
as speciﬁc conditions as carpal tunnel syndrome (CTS),
tenosynovitis, tendinopathies, and polyarthralgias of the
hands and ﬁngers or as nonspeciﬁc mono- or oligoarthral-
gias. The incidence of these symptoms has been reported
to vary between 5 to 35%, and almost one-third of these
patients discontinued therapy due to severity of the symp-
toms.
2.CaseReport
A 48-year-old postmenopausal woman with an early breast
cancer (T1b, N0, M0, ER(+), PgR(+), HER-2(−)) was
referred to our department in December 2009. She was
initially treated by lumpectomy and subsequently by oral
letrozole. Nine weeks after treatment’s initiation the patient
claimed progressive worsening of bilateral pain to the radial
surface of the wrists and important functional impairment.
Finally, pain caused rising from her sleep.
On clinical examination, severe sensory paraesthesias
presented to the dorsal surface of the wrists and to the base
of thumbs. Inﬂammatory signs became apparent as well as
palpable nodule with a “bounce” feeling at the movement
of the thumb. Moreover, the clinical evaluation revealed
bilateral positive Finkelstein’s test, which is characteristic of
De Quervain syndrome (stenosing tenosynovitis). This test
in combination with the described anatomic location of the
painonthethumbsideoftheforearm,abouttwocentimeters
below the wrist, rules out the diagnosis of intersection2 Case Reports in Medicine
syndrome. Furthermore, the negative imaging studies per-
formed (X rays) excluded the diagnosis of osteoarthritis
of the ﬁrst carpometacarpal joint. In addition, a negative
electromyogram excluded the diagnosis of Wartenberg’s
syndrome. Additional laboratory studies were performed
and exclude systematic inﬂammatory process or ﬁndings
indicative of autoimmune disease. The patient reported no
use of other medications or other health conditions. Finally,
it was conﬁrmed that the patient did not have overuse
injuries due to daily repeated movements of the thumb,
which could cause stress tendinitis from lassitude.
Initially, the patient was treated with compression ban-
dages to immobilize the wrists and oral nonsteroidal anti-
inﬂammatory drug, which failed to relieve the symptoms.
Consequently, interruption of letrozole was recommended
and, ﬁve weeks later, the patient reported progressive
improvement up to complete regression of symptoms. After
two months of interruption of letrozole and total disappear-
anceofsymptoms,thepatientwasstartedonexemestaneand
the syndrome did not reappear after start of the latter. To our
knowledge, this is the ﬁrst report of bilateral De Quervain
syndrome probably related with AIs therapy.
3. Discussion
Musculoskeletal symptoms are often described in patients
treated with AIs. Although the term “arthralgias” is com-
monly used, the lack of uniform assessment of these
symptoms in diﬀerent studies created the large diversity in
the clinical entities described. AI-related arthralgia has been
reported throughout the whole musculoskeletal system but
is particularly common in the anatomic region of wrist
joint [1–3]. Relevant clinical conditions reported include
CTS,tenosynovitis,“triggerﬁnger,”morningstiﬀness,aswell
as tendinopathies, polyarthralgias, or nonspeciﬁc mono- or
oligoarthralgias and eﬀusions of the hand and wrist [4–
7]. Daily activity restrain, related to musculoskeletal distur-
bances from AIs use, has not been studied systematically,
and it is often underestimated. In some cases, it has been
the reason for discontinuation of treatment and constitutes
serious cause of kinetic loss [1]. In a small group of patients,
switching to another AI allows continuation of therapy and
therefore maintains the expected beneﬁt in disease outcome.
The incidence of musculoskeletal events varies between
5% and 35%, with CTS and “trigger ﬁnger” being the most
frequent [8]. In addition, estrogen deprivation caused by
AIs induces bone mineral density decrease and fragility
fractures which may represent another common cause of
musculoskeletal symptoms.
Unfortunately, the heterogeneity of symptoms is pro-
portional to high diversity in imaging, laboratory, and
pathological ﬁndings, rending diagnosis and understanding
of AI-related joint pain pathophysiology a diﬃcult task.
In fact, some studies involving ultrasound or magnetic
resonance imaging (MRI) have documented tendon, tendon
sheath,andsynovialchangesobservedinpatientswithsevere
AI-induced musculoskeletal symptoms. On the other hand,
a large body of clinical trials in patients treated with AIs
relies the diagnosis of relative situations like trigger ﬁnger,
intersection syndrome, or “arthritis” on clinical ﬁndings
without essential report of imaging results [3, 4].
More studies conﬁrmed signiﬁcant thickening of the
digital ﬂexor tendon synovial sheath on MRI [5, 6]. Fur-
thermore, no abnormalities have been usually seen with
radiographs or bone scintigraphy [5]. Though, it is to be
noted that the results for arthritis ﬁndings in imaging studies
may vary depending on underline situations such as the
degree of osteoporosis, osteoarthritis, or rheumatopathies
[5,6].NerveconductionstudiesandEMGtesting,inpatients
with AI-induced symptoms suggestive of CTS, have been
also performed; varying levels of median mononeuropathy
at the wrist have been reported. Finally, studies evaluating
systemic inﬂammatory and autoimmune markers in patients
with aromatase inhibitor-associated tendinopathy, such as
ESR, CRP, RF, antinuclear antibody, anti-double-stranded
DNA antibody, and anticyclic citrullinated peptide antibody,
have not identify a correlation [5, 6]. Only one prospective
study focusing on this aspect showed a minor elevation of
systemic inﬂammatory markers [7].
Although the pathogenesis is unknown, postulated
mechanisms have been described. A rational explanation
for these symptoms could be related to the fact that
estrogen levels interfere with body hydratation status. It
could be speculated that they keep the body “moist” and
that, without estrogen, everything dries up, including the
joints. Without “lubrication,” the joints get irritated and
then swollen. Unfortunately, pathogenesis of this condition
is much more complicated and not well known. Recently,
there is a tendency of classiﬁcation of these symptoms into
two general categories: (a) joint pain as in arthritis and (b) a
more generalized discomfort involving muscle and skeleton,
what the bibliography calls aromatase inhibitor arthralgia
(AIA). Extensive research is evolving for its understanding,
and diﬀerent approaches are reported.
AIA is more likely related to estrogen deprivation that
leads to suspension of their antinociceptive eﬀects. Mech-
anisms of joint pain include enhanced nociception due to
estrogen depletion. Evidence exists that estrogen may have
an antinociceptive and pain-modulating eﬀects, and it is
known to have eﬀects on opioid-related receptors in the
centralnervoussystem[8].Indeed,invitrodataconﬁrmthat
estrogen-receptor-positive cells express preproenkephalin
messenger RNA, and also estrogen given to ovariectomized
animals increases enkephalin transcription in the spinal cord
[9]. These neurons provide critical inhibition of nociceptive
neurons.
Another study proved that opioid-receptor-like 1 (ORL1)
mRNA is present in the majority of estrogen receptor
mRNA-containing neurons. The study concludes that sex-
related diﬀerences in the ORL1-receptor gene expression
in the trigeminal nucleus caudalis appear to be aﬀected
by estrogen levels [10]. Estrogen receptors are also present
in brain as estrogen treatment stimulates the release of
endogenous opioids that activate mu-opioid receptor (mu-
OR) in the limbic system and hypothalamus providing a
“neurochemical signature” of steroid activation of these
circuits[11].Takentogether,theseinvitrodataimplyanevenCase Reports in Medicine 3
more direct eﬀect of estrogen on opioid generation locally.
These observations are further supported by clinical trials
for nociception variations in women during their menstrual
cycle and menopause.
In fact, joint symptoms in postmenopausal women de-
scribedas“Menopausalarthritis”wereﬁrstdescribedin1925
[12]. Women during pregnancy have elevated thresholds
for painful stimuli in the presence of increased levels of
estrogen [13]. Furthermore, in nonpregnant animals in
which pregnancy levels of estradiol and progesterone are
simulated, pain thresholds rise [14]. In women treated with
hormone replacement therapy, a signiﬁcantly lower chance
for developing musculoskeletal symptoms was reported
[15]. These data support the hypothesis that high levels
of gonadal hormones suppress pain sensitivity. However,
hormone replacement therapy has not proven its eﬃcacy as
adequatetreatmentforarthralgiainpostmenopausalwomen
[16].
There is no doubt that the speciﬁc eﬀects of aromatase-
containing cells on nociceptive ﬁbers are less understood
than the direct eﬀects of estrogen. In breast cancer patients
under treatment with AIs, joint pain appears also to relate
with the “anti-nociceptive eﬀects” of estrogens and consec-
utive increase of pain threshold [14, 17]. Opposite though
were the results of an early meta-analysis in healthy women
across their menstrual cycle, which demonstrate much
better pain tolerance during times of lowest estradiol and
progesterone levels of the menstrual cycle [18]. Diﬀerences
in the methodology of pain registration in the literature may
explain some of the conﬂicting results.
No speciﬁc eﬀectsofestrogenonarticularstructureshave
been reported, but it inﬂuences inﬂammation and neural
processing of nociceptive input [14]. There are also data
available for inﬂammatory process activation via autoim-
mune pathways, after therapy with AIs [19, 20]. However, as
previously noted, updated data in patients on AI treatment
do not conﬁrm an increased incidence of autoimmunity or
raised systemic inﬂammatory markers. Little data exist on
inﬂammatoryeﬀectsofestrogenswithinthejoint,buttissue-
speciﬁc eﬀects of estrogen on inﬂammatory cytokines have
been reported [14, 21]. Characteristically, while estrogen
enhances nitric oxide production in endothelial cells, it
inhibits nitric oxide and prostaglandin E2 production in
microglia [22]. There is also evidence that the proinﬂamma-
tory cytokines, Il-1, Il-6, and TNF-alpha, are elevated in the
ﬁrst few years after the menopause, when estrogen levels are
lower and the incidence of joint symptoms is high [23].
When a joint is inﬂamed, mediators such as pros-
taglandins and bradykinin could also activate receptors
on peripheral nociceptors, enhancing their sensitivity to
pain and also neuron’s nociceptive receptor ﬁelds enlarge
[23]. Probably inﬂammation in the joint could account for
enhanced nociception that occurs with estrogen depletion.
In a study on synoviocytes, in which aromatase was
showntoconvertandrostenedionetooestradiol,Il-6produc-
tion was reduced [24, 25]. Therefore, reduction of oestradiol
may promote local inﬂammatory changes in the joint by
this mechanism. Evidence exists that the proinﬂammatory
cytokines, Il-1, Il-6, and TNF-alpha, are spontaneously
elevated in the ﬁrst few years after the menopause a time
when the natural incidence of joint symptoms is high [26].
Indeed, it hasbeen suggestedthattime since menopause may
be an important predictive factor for AIA, and this may be
linked to cytokine activity [26, 27].
Ad i ﬀerent approach on AIA pathogenesis is that of
a recent study, correlating the role of estrogen depletion
on melatonin secretion and joint pain. The authors make
two interesting clue points: the observation that joint pain
is associated with virtually all estrogen-depleting breast
cancer treatments suggests that the cause is broader than
the case of AIs, and, second, usually the discomfort is
worse in the morning and the strongly circadian nature of
these symptoms suggests circadian hormone involvement.
Estrogen depletion could increase pineal melatonin, and, in
addition, the ability of light to suppress pineal melatonin
is more variable than once thought and that an altered
melatonin cycle is associated with rheumatoid arthritis
patients, where identical circadian symptoms present. It is
hypothesized that when AIs decrease estrogen levels, light-
induced melatonin suppression loses eﬃcacy, leading to an
abnormal melatonin cycle as seen in rheumatoid arthritis
patients, producing the symptoms of morning stiﬀness [28].
This study suggests that suppressing melatonin production
by light exposure will reduce the pain in women on AIs.
Interestingly, in one patient, symptoms were relieved by
spending lots of time outside.
One more ﬁeld of clinical research for AIA pathogenesis,
independently of the possible mechanism, is the possible
contribution of an extensive spectrum of diseases that
typically induce musculoskeletal symptoms. There is a high
background level of joint symptoms in the peri- and
postmenopausal female population and it is important to
consider this when evaluating the incidence and etiology
of AIA [29]. It is known that the incidence of joint pain
peaks at 50–59 years in the general population. Some
preclinical studies have shown a protective eﬀect of estrogen
in arthritis and on proinﬂammatory genes. Clearly, there are
several possible causes of arthralgia in a nonbreast cancer
population, which can make it diﬃcult to elucidate one
particular cause. Other studies have also shown that BMI is
associatedwithanincreasingriskofjointpain.Theincidence
of pain in at least one joint has been as high as 49%
[30].
The increased prevalence of carpal tunnel syndrome is
one of the clinical expressions of AIA. A possible explanation
could be compression neuropathy of the median nerve due
to the presence of ﬂuid around the ﬂexor tendons and
edema of the wrist, as previously noted. In a relative study
of nonbreast cancer patients undergoing surgery for carpal
tunnel syndrome, tissue from the transverse carpal ligament
and synovium was examined and found to highly express ER
and PR. This observation potentially reveals a role of these
receptors in the pathogenesis of carpal tunnel syndrome.
Interestingly, the number of ER-positive cells increased with
age to a peak at 55–70, decreasing thereafter [31].
To our knowledge, this is the ﬁrst report of bilateral
De Quervain syndrome related with an AI therapy. Switch
to another AI due to severe side eﬀects could be an4 Case Reports in Medicine
option. Further research will probably give prospects for new
predictive markers, while the study of pathological changes
inconcreteanatomicsitesoftendonsheathwillprobablylead
to comprehension of parallel mechanisms of AIs action and
tailored made symptomatic therapy.
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